AIM
AMRX icon

Artemis Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Artemis Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Hold
186,125
– – 0.03% 176
2026
Q1 		$2.31M Buy
186,125
+61,226
+49% +$822K 0.02% 176
2025
Q4 		$1.57M Buy
+124,899
New +$1.43M 0.02% 178

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Artemis Investment Management's AMRX Position: Q2 2026 in Review

Artemis Investment Management held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 186,125 shares worth $3.22M. The position accounts for 0.03% of the portfolio, ranked #176.

Artemis Investment Management first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Artemis Investment Management held 186,125 shares of Amneal Pharmaceuticals worth $3.22M as of Q2 2026.
  • Artemis Investment Management left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
  • Amneal Pharmaceuticals made up 0.03% of Artemis Investment Management's portfolio in Q2 2026, its #176 holding.
  • Artemis Investment Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Artemis Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.